HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,650.00
-65.00 (-1.75%)
May 15, 2026, 3:30 PM KST
Market Cap456.93B -40.1%
Revenue (ttm)45.75B +39.6%
Net Income-99.79B
EPS-819.00
Shares Out121.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume363,903
Average Volume394,156
Open3,730.00
Previous Close3,715.00
Day's Range3,600.00 - 3,790.00
52-Week Range3,105.00 - 6,490.00
Betan/a
RSI32.48
Earnings DateMay 21, 2026

About HLB Life Science

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various ... [Read more]

Sector Utilities
Founded 1998
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements